Market Overview

Data Projects the CBD Industry to Eclipse USD 2 Billion by 2022


Data Projects the CBD Industry to Eclipse USD 2 Billion by 2022 News Commentary

PR Newswire

NEW YORK, August 22, 2018 /PRNewswire/ --

According to recent data provided by New Frontier Data, the U.S. CBD industry grew by nearly 40% in 2017, reaching USD 367 Million in sales across hemp-derived and marijuana-derived markets. This is the first year in which sales of hemp-derived CBD products outpaced marijuana-derived CBD products. The report also clarifies that surging demand is projected to lift both of the markets higher. This year (2018) is expected to be a break-out year for CBD products, as total market expansion is expected to cross the USD 500 Million mark in sales. The CBD industry will grow to USD 1.2 Billion by 2020, and nearly USD 2 Billion by 2022. CLS Holdings USA Inc. (OTC:CLSH), Lexaria Bioscience Corp. (OTC:LXRP), Leafbuyer Technologies Inc. (OTC:LBUY), The Supreme Cannabis Company Inc. (OTC:SPRWF), Namaste Technologies Inc. (OTC:NXTFF)

New Frontier Data CEO, Giadha Aguirre de Carcer, explained, "The U.S. CBD market is primed for expansive growth across its three primary sectors, hemp-derived CBD, marijuana-derived CBD and pharmaceutical CBD. We have already observed market shifts in 2017 as the hemp-derived CBD sector outpaced marijuana-derived CBD for the first time, and we expect to see continued changes as the pharmaceutical sector officially opens in 2018. We project that by 2022, each of these three sectors will account for approximately one-third of the USD 1.9 Billion total market."

CLS Holdings USA Inc. (OTCQB:CLSH) yesterday announced breaking news that, "Matthew Janz has joined the Company as VP of Marketing and Director of Operations at Oasis Cannabis.

Mr. Janz, previously the Regional Marketing Manager at Apothecarium, will lead the new marketing initiative programs at Oasis Cannabis, with a focus in digital marketing and social media engagement, and with attention to creative tact. He will orchestrate and implement all SEO, SEM, E-mail, Social, and AdWord work.

Matthew Ganz, VP of Marketing and Director of Operations at Oasis Cannabis, stated, 'I am excited to be a part of the Oasis Cannabis team. My expertise of creating innovative marketing solutions has been very successful in the cannabis industry with consistent conversions and building long-term growth. I'm looking forward to continuing that work with Oasis and helping improve their visibility, awareness and market penetration in the Las Vegas market.'

Jeff Binder, Chief Executive Officer of CLS, commented, "I am pleased to welcome Matt to our CLS and Oasis team. Given his previous success at Apothecarium, we are confident in his marketing abilities and believe he will make key improvements in our marketing strategy. We look forward to the increased visibility for Oasis as we look to expand the growth opportunities for Oasis and CLS."

About Oasis Cannabis ( Oasis Cannabis has operated a cannabis dispensary in the Las Vegas market since dispensaries first opened in Nevada in 2015 and has been recognized as one of the top marijuana retailers in the state. Its location within walking distance to the Las Vegas Strip and Downtown Las Vegas in combination with its delivery service to residents allows it to efficiently serve both locals and tourists in the Las Vegas area. The company recently commenced wholesale offerings of cannabis in Nevada with the launch of its City Trees brand of cannabis concentrates and cannabis-infused products in August 2017. An expansion of its cultivation and production facility is currently underway and is expected to be completed during the fourth quarter of 2018."

Lexaria Bioscience Corp. (OTCQX:LXRP) has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. The Company recently reported significant bioavailability results from its randomized, placebo-controlled, double-blind European human clinical study that evaluated TurboCBDTM - a proprietary, DehydraTECH™ powered, cannabidiol ("CBD") fortified hemp oil capsule developed by Lexaria. The degree and speed of CBD absorption into blood plasma and potential cardiovascular and cognitive performance enhancement in 12 healthy male volunteers were studied. These results corroborate and confirm earlier in vitro and in vivo studies that have evaluated Lexaria's Dehydra TECHTM technology and have consistently measured higher levels of drug delivery much more quickly than positive controls with matching CBD concentrations. Although this study evaluated absorption only of CBD and its metabolites, Lexaria believes nearly identical bioavailability enhancement results would be achieved if the cannabinoid studied was THC instead of CBD. Lexaria was also pleased that, as expected, blood levels of THC, 11-OH-THC, and THCCOOH were non-detectable, highlighting the absence of THC and the extraordinary CBD purity within the TurboCBDTM capsules. Additional data is still being gathered and analyzed from the study, including other pharmacokinetic study parameters including metabolic data and the outcomes of the cardiovascular and cognitive performance measures that the study also evaluated.

Leafbuyer Technologies Inc.  (OTCQB:LBUY) is a leading cannabis technology platform. The Company has recently announced that sales growth has increased by over 50% from Q4 2017 to Q4 2018. This growth comes on the back of continued expansion into new markets as well as increased product offerings, such as online pre-ordering and the company's loyalty program. "Expansion plans started 9 months ago in Oregon, Washington, California, Nevada, and Arizona, and we are capitalizing on those markets," said John Valle, Director of Sales for Leafbuyer Technologies Inc. "We are pleased with our growth, and with California continuing its transition from non-licensed shops to licensed shops, we believe we are in a great position to work with those companies from day one."

The Supreme Cannabis Company Inc. (OTC:SPRWF) is a Canadian publicly traded company committed to providing premium brands and products that proudly reflect its consumers, people and uniquely innovative culture. Supreme Cannabis recently announced that the Company's wholly owned subsidiary, 7ACRES, has entered into a supply agreement with the Ontario Cannabis Store ("OCS") to supply cannabis for online sales when the recreational market launches on October 17th, 2018. Under the agreement, 7ACRES will also supply recreational cannabis to Ontario's private retailers when the retail framework is approved and implemented by the Province. The supply agreement is for a 24-month period with renewal options. As the province releases more information on category listings, the Company will provide further updates. In all provincial supply agreements secured to date (British Columbia, Alberta, and Manitoba), 7ACRES products have been listed at the highest brand category. "With Ontario expected to be the largest recreational cannabis market in the nation, this supply agreement is a major milestone for our Company," said John Fowler, Chief Executive Officer of Supreme Cannabis. "We anticipate the full 7ACRES lineup will be placed in the premium category by the OCS validating the quality of our product offerings and our strategy of catering to discerning cannabis enthusiasts who, by the Ontario government's own estimation, will drive the majority of recreational sales."

Namaste Technologies Inc. (OTCQB:NXTFF) is Your Everything Cannabis Store™. Namaste operates the largest global cannabis e-commerce platform with over 30 websites in 20+ countries under various brands. Nameste recently announced that the Company's wholly-owned subsidiary, Cannmart Inc., a licensed cannabis producer under the Access to Cannabis for Medical Purposes Regulations, has completed Health Canada's Pre-Sales License Inspection at the Cannmart facility in Etobicoke, Ontario. On July 31st, 2018, Health Canada inspectors were on-site to verify information submitted by Cannmart as part of its application and in assessing compliance with the applicable sections of the ACMPR prior to license approval. The Pre-Sales License Inspection is one of the last steps prior to the issuance of a Sales License under the ACMPR. In anticipation of its upcoming ACMPR Sales License, Namaste is focused on accelerating patient acquisition through the launch of its updated version of the NamasteMD mobile app and by initiating several strategic marketing initiatives.

Subscribe Now! Watch us report LIVE

Follow us on Twitter for real time Financial News Updates:

Follow and talk to us on Instagram:

Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For CLS Holdings USA Inc. financial news dissemination and PR services, has been compensated five thousand dollars by the company Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit:

Media Contact:




View Comments and Join the Discussion!